Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M E Gore

Showing results (131-140 of 157) with videos related to

Pageof 16
Sort By:
British Journal of Cancer|May 23, 2013
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinomaR J Motzer, B Escudier, R Bukowski, et al.
British Journal of Cancer|October 1, 1996
A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanomaF Y Ahmed, G A Leonard, R A'Hern, et al.
British Journal of Cancer|December 6, 2006
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanomaJ M G Larkin, S A Hughes, D A Beirne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1989
Carboplatin dosage: prospective evaluation of a simple formula based on renal functionA H Calvert, D R Newell, L A Gumbrell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2023
Carboplatin dosage: prospective evaluation of a simple formula based on renal functionA H Calvert, D R Newell, L A Gumbrell, et al.
British Journal of Cancer|September 16, 2010
A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinomaJ M G Larkin, T R Ferguson, L M Pickering, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 4, 2000
GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanomaM M Vaughan, J Moore, P G Riches, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1988
Phase I and pharmacokinetic studies with the pentacyclic pyrroloquinone mitoquidoneP A Speth, M E Gore, A J Pateman, et al.
Gynecologic Oncology|November 16, 2011
Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC)D F Kolomainen, A Daponte, D P J Barton, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT)M E Gore, J Bellmunt, T Eisen, et al.
Pageof 16

Showing results (131-140 of 157) with videos related to

Sort By:
Pageof 16
British Journal of Cancer|May 23, 2013
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinomaR J Motzer, B Escudier, R Bukowski, et al.
British Journal of Cancer|October 1, 1996
A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanomaF Y Ahmed, G A Leonard, R A'Hern, et al.
British Journal of Cancer|December 6, 2006
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanomaJ M G Larkin, S A Hughes, D A Beirne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1989
Carboplatin dosage: prospective evaluation of a simple formula based on renal functionA H Calvert, D R Newell, L A Gumbrell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2023
Carboplatin dosage: prospective evaluation of a simple formula based on renal functionA H Calvert, D R Newell, L A Gumbrell, et al.
British Journal of Cancer|September 16, 2010
A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinomaJ M G Larkin, T R Ferguson, L M Pickering, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 4, 2000
GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanomaM M Vaughan, J Moore, P G Riches, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1988
Phase I and pharmacokinetic studies with the pentacyclic pyrroloquinone mitoquidoneP A Speth, M E Gore, A J Pateman, et al.
Gynecologic Oncology|November 16, 2011
Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC)D F Kolomainen, A Daponte, D P J Barton, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT)M E Gore, J Bellmunt, T Eisen, et al.
Pageof 16